Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The current book comprises a series of chapters from experts in the field of myeloid cell biology and myeloid leukemia pathogenesis. It is meant to provide reviews about current knowledge in the area of basic science of acute (AML) and chronic myeloid leukemia (CML) as well as original publications covering specific aspects of these important diseases. Covering the specifics of leukemia biology and pathogenesis by authors from different parts of the World, including America, Europe, Africa, and Asia, this book provides a colorful view on research activities in this field around the globe.

Myeloid leukemia. --- Granulocytic leukemia --- Myelogenous leukemia --- Myelocytic leukemia --- Bone marrow --- Nonlymphoid leukemia --- Diseases --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. .

Medicine. --- Hematology. --- Medicine & Public Health. --- Chronic myeloid leukemia. --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Chronic leukemia --- Myeloid leukemia --- Haematology --- Internal medicine --- Blood --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria. .

Chronic myeloid leukemia --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Chronic leukemia --- Myeloid leukemia --- Hematology. --- Oncology  . --- Oncology. --- Pharmacotherapy. --- Tumors --- Haematology --- Internal medicine --- Blood --- Diseases --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Pharmacology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume provides a comprehensive, state-of-the art review of myeloid neoplasms. The book presents updated information on epidemiology, clinical presentation, morphologic findings, molecular genomic abnormalities, pathogenesis, and target therapies. The text helps to guide accurate diagnosis, the administration of appropriate ancillary molecular tests, patient management, and investigative efforts. Written by experts in the field, Precision Molecular Pathology of Myeloid Neoplasms serves as a valuable resource for pathologists, hematologists/oncologists, fellows, and researchers in understanding the molecular pathology of myeloid neoplasms. .

Medicine. --- Hematology. --- Oncology. --- Pathology. --- Medicine & Public Health. --- Disease (Pathology) --- Haematology --- Clinical sciences --- Medical profession --- Medical sciences --- Diseases --- Medicine --- Medicine, Preventive --- Tumors --- Internal medicine --- Blood --- Human biology --- Life sciences --- Pathology --- Physicians --- Chronic myeloid leukemia --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Chronic leukemia --- Myeloid leukemia --- Oncology  .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas, and both basic and clinical scientists will benefit from this translational text.

Medicine & Public Health. --- Hematology. --- Oncology. --- Cancer Research. --- Internal Medicine. --- Medicine. --- Internal medicine. --- Médecine --- Cancérologie --- Médecine interne --- Hématologie --- Acute myeloid leukemia. --- Leukemia, Myeloid, Acute. --- Acute myeloid leukemia --- Leukemia, Myeloid, Acute --- Leukemia, Myeloid --- Leukemia --- Neoplasms by Histologic Type --- Neoplasms --- Diseases --- Pathology --- Hematologic Diseases --- Medicine --- Health & Biological Sciences --- Leukemia. --- Leucaemia --- Leucemia --- Leucocythaemia --- Leucocythemia --- Leucosis --- Leukaemia --- Leukosis --- Acute myelogenous leukemia --- Acute myeloid granulocytic leukemia --- Acute myelocytic leukemia --- AML (Disease) --- Cancer research. --- Anemia --- Cancer --- Leucocytosis --- Preleukemia --- Acute leukemia --- Myeloid leukemia